2024
Long-term Safety And Tolerability Of Acoramidis (AG10) In Symptomatic Transthyretin Amyloid Cardiomyopathy: 4-year Update From An Ongoing, Phase 2, Open-label Extension Study
Masri A, Aras M, Falk R, Grogan M, Jacoby D, Maurer M, Shah S, Witteles R, Wong P, Ji A, Du J, Siddhanti S, Sinha U, Fox J, Judge D. Long-term Safety And Tolerability Of Acoramidis (AG10) In Symptomatic Transthyretin Amyloid Cardiomyopathy: 4-year Update From An Ongoing, Phase 2, Open-label Extension Study. Journal Of Cardiac Failure 2024, 30: 221. DOI: 10.1016/j.cardfail.2023.10.251.Peer-Reviewed Original ResearchOpen-label extensionATTR-CMAmyloid cardiomyopathyPhase 3 randomized clinical trialMedian NT-proBNP levelOpen-label extension studyNYHA class IIMedian follow-upNT-proBNP levelsPhase 2 studyPhase 2 trialTransthyretin amyloid cardiomyopathyNT-pro-BNPOpen-label studyLong-term treatmentLong-term safetyEx vivo assaysDouble-blindPlacebo-controlledNT-proAdverse eventsFollow-upClinical trialsConcurrent illnessDay 1
2020
Evaluating Recruitment Strategies for a Randomized Clinical Trial with Heart Failure Patients
Conley S, O’Connell M, Linsky S, Moemeka L, Darden JW, Gaiser EC, Jacoby D, Yaggi H, Redeker NS. Evaluating Recruitment Strategies for a Randomized Clinical Trial with Heart Failure Patients. Western Journal Of Nursing Research 2020, 43: 785-790. PMID: 33158412, PMCID: PMC8099934, DOI: 10.1177/0193945920970229.Peer-Reviewed Original ResearchConceptsClinic-based recruitmentMultiple recruitment strategiesPatient portalsClinical trialsElectronic databasesChronic stable heart failureElectronic medical record databaseRecruitment strategiesStable heart failureHeart failure patientsChronic medical conditionsRandomized clinical trialsMedical record databaseBaseline data collectionCognitive behavioral therapyFailure patientsHeart failureMedical recordsMedical conditionsPatientsRecruitment goalsRecord databaseBehavioral therapySupport groupsTrials